Novel agents to override imatinib resistance mechanisms.
- Published in:
- Drug Development Research, 2008, v. 69, n. 7, p. 398, doi. 10.1002/ddr.20271
- By:
- Publication type:
- Article
Works matching IS 02724391 AND DT 2008 AND VI 69 AND IP 7
Results: 9
1
2
Newly developed effective anti-cancer drugs targeting multiple myeloma.
- Published in:
- Drug Development Research, 2008, v. 69, n. 7, p. 451, doi. 10.1002/ddr.20275
- By:
- Publication type:
- Article
3
Neoadjuvant therapy as a paradigm to develop systemic cancer therapy.
- Published in:
- Drug Development Research, 2008, v. 69, n. 7, p. 388, doi. 10.1002/ddr.20270
- By:
- Publication type:
- Article
4
Development of drugs against hormone-refractory prostate cancer.
- Published in:
- Drug Development Research, 2008, v. 69, n. 7, p. 431, doi. 10.1002/ddr.20274
- By:
- Publication type:
- Article
5
Recent advances in the development of novel anti-cancer drugs targeting cancer stem/progenitor cells.
- Published in:
- Drug Development Research, 2008, v. 69, n. 7, p. 415, doi. 10.1002/ddr.20273
- By:
- Publication type:
- Article
6
Pan-HER biologics (Hermodulins) for the treatment of cancer.
- Published in:
- Drug Development Research, 2008, v. 69, n. 7, p. 472, doi. 10.1002/ddr.20277
- By:
- Publication type:
- Article
7
Molecular targeting with recombinant cytotoxins for the treatment of brain tumors.
- Published in:
- Drug Development Research, 2008, v. 69, n. 7, p. 407, doi. 10.1002/ddr.20272
- By:
- Publication type:
- Article
8
Natural products and colon cancer: current status and future prospects.
- Published in:
- Drug Development Research, 2008, v. 69, n. 7, p. 460, doi. 10.1002/ddr.20276
- By:
- Publication type:
- Article
9
Treatment of chronic lymphoid leukemias with monoclonal antibodies: current place and perspectives.
- Published in:
- Drug Development Research, 2008, v. 69, n. 7, p. 373, doi. 10.1002/ddr.20269
- By:
- Publication type:
- Article